D. Western Therapeutics Institute
4576
Wintest
6721
Ridge-i
5572
River Eletec
6666
Heartseed
219A
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 17.02%14.86B | 23.17%4.04B | 4.91%4.06B | 18.96%3.32B | 24.77%3.44B | 16.78%12.7B | 3.20%3.28B | 23.42%3.87B | 13.57%2.79B | 31.18%2.75B |
Cost of revenue | 26.61%5.07B | 35.63%1.45B | 15.61%1.36B | 26.64%1.12B | 30.26%1.14B | 13.58%4.01B | -0.38%1.07B | 20.19%1.17B | 15.90%881.83M | 23.11%878.94M |
Gross profit | 12.61%9.79B | 17.13%2.59B | 0.26%2.71B | 15.42%2.2B | 22.19%2.29B | 18.31%8.69B | 5.02%2.21B | 24.88%2.7B | 12.53%1.91B | 35.34%1.87B |
Operating expense | 25.78%7.66B | 39.68%2.1B | 17.70%2B | 23.37%1.84B | 23.21%1.71B | 19.33%6.09B | 6.31%1.51B | 25.86%1.7B | 22.96%1.49B | 23.96%1.39B |
Operating profit | -18.23%2.13B | -31.08%485.47M | -29.47%704.01M | -13.20%360.55M | 19.27%578.01M | 16.00%2.6B | 2.37%704.35M | 23.24%998.18M | -13.78%415.39M | 83.69%484.6M |
Net non-operating interest income (expenses) | 47.42%8.01M | 123.68%2.92M | 92.65%2.02M | 7.09%1.6M | -7.12%1.47M | -11.67%5.43M | -12.36%1.31M | -31.88%1.05M | -11.64%1.5M | 10.68%1.59M |
Non-operating interest income | 47.42%8.01M | 123.68%2.92M | 92.65%2.02M | 7.09%1.6M | -7.12%1.47M | -12.03%5.43M | -12.36%1.31M | -31.88%1.05M | -12.00%1.5M | 9.30%1.59M |
Net investment income | -21.13%1.81M | 0 | 0 | 33.33%720K | 5.19%1.09M | 8.49%2.3M | 33.33%720K | 0 | 0.00%540K | 0.00%1.04M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 89.26M | 0 | 0 | 0 | ||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | -86.40%99K | 0 | 99K | 0 | 0 | -68.32%728K | -168.35%-203K | 0 | 0 | -51.28%931K |
Less:Other special charges | 86.40%-99K | --0 | ---- | ---- | ---- | 65.61%-728K | 180.88%203K | --0 | --0 | 50.11%-931K |
Other non-operating income (expenses) | -38.67%6.05M | -48.34%1.01M | -70.01%1.01M | -27.89%1.03M | -3.76%3M | 118.73%9.86M | 204.50%1.96M | 586.09%3.36M | 59.26%1.43M | 25.71%3.12M |
Income before tax | -14.79%2.23B | -30.89%489.4M | -20.57%796.4M | -13.12%363.9M | 18.79%583.57M | 16.04%2.62B | 2.48%708.13M | 23.47%1B | -13.63%418.85M | 81.49%491.28M |
Income tax | -15.61%624.05M | -56.39%40.67M | -19.51%270.04M | -19.73%102.92M | 15.26%210.43M | 4.10%739.5M | -46.01%93.25M | 21.66%335.48M | -18.51%128.21M | 74.57%182.56M |
Net income | -14.46%1.61B | -27.02%448.73M | -21.10%526.36M | -10.20%260.99M | 20.87%373.14M | 21.52%1.88B | 18.64%614.89M | 24.40%667.11M | -11.28%290.64M | 85.85%308.72M |
Net income continuous operations | -14.46%1.61B | -27.02%448.73M | -21.10%526.36M | -10.20%260.99M | 20.87%373.14M | 21.52%1.88B | 18.64%614.89M | 24.40%667.11M | -11.28%290.64M | 85.85%308.72M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | -14.46%1.61B | -27.02%448.73M | -21.10%526.36M | -10.20%260.99M | 20.87%373.14M | 21.52%1.88B | 18.64%614.89M | 24.40%667.11M | -11.28%290.64M | 85.85%308.72M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -14.46%1.61B | -27.02%448.73M | -21.10%526.36M | -10.20%260.99M | 20.87%373.14M | 21.52%1.88B | 18.64%614.89M | 24.40%667.11M | -11.28%290.64M | 85.85%308.72M |
Gross dividend payment | ||||||||||
Basic earnings per share | -14.46%110.28 | -27.01%30.75 | -21.11%36.07 | -10.15%17.89 | 20.84%25.57 | 21.36%128.92 | 18.58%42.13 | 24.31%45.72 | -11.43%19.91 | 84.97%21.16 |
Diluted earnings per share | -14.46%110.28 | -27.01%30.75 | -21.10%36.07 | -10.17%17.8848 | 20.84%25.57 | 21.47%128.92 | 18.61%42.13 | 24.36%45.7152 | -11.31%19.91 | 85.61%21.16 |
Dividend per share | 11.76%38 | 11.76%19 | 0 | 11.76%19 | 0 | 13.33%34 | 13.33%17 | 0 | 13.33%17 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |